What is the recommended dosing of clonidine (antihypertensive medication) for the management of night sweats?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Clonidine Dosing for Night Sweats

For night sweats, clonidine can be administered at a dose of 0.1 mg twice daily initially, with gradual titration up to 0.2-0.6 mg daily in divided doses based on response and tolerability. 1

Dosing Regimen

  • Start with 0.1 mg twice daily (morning and bedtime) as the initial dose 1
  • Elderly patients may benefit from a lower initial dose 1
  • Increase by 0.1 mg per day at weekly intervals if necessary until desired response is achieved 1
  • Taking the larger portion of the daily dose at bedtime may minimize side effects such as dry mouth and drowsiness 1
  • For night sweats specifically, doses of 0.1-0.2 mg at bedtime have shown efficacy 2
  • For PTSD-associated nightmares, doses of 0.2-0.6 mg daily (in divided doses) have been effective 2

Mechanism of Action for Night Sweats

  • Clonidine is an α2-adrenergic receptor agonist that suppresses sympathetic nervous system outflow throughout the brain 2
  • It produces a dose-dependent reduction in norepinephrine appearance rate in plasma, which may help reduce night sweats 3
  • Clonidine decreases vasoconstriction and shivering thresholds without affecting the sweating threshold, which helps regulate temperature control during sleep 4
  • Low-dose clonidine increases REM sleep while medium-dose clonidine decreases REM sleep and increases N2 sleep, which may contribute to its effects on night sweats 2

Evidence for Efficacy

  • Clonidine has shown mild to moderate efficacy in treating menopausal hot flashes, reducing them by up to 46% 2
  • In tamoxifen users with breast cancer history, transdermal clonidine (0.1 mg/day) or oral clonidine (0.1 mg/day) reduced frequency and severity of hot flashes 2
  • For PTSD-associated nightmares, case series have demonstrated efficacy of 0.2-0.6 mg clonidine in divided doses 2
  • In a 2-week pilot study, 0.1 mg clonidine twice daily decreased frequency of nightmares in patients with PTSD 2

Monitoring and Side Effects

  • Monitor for orthostatic hypotension, especially when increasing doses 2
  • Common side effects include dry mouth and insomnia or drowsiness 2
  • Clonidine can cause significant sedation - a morning dose of 0.25-0.3 mg produced profound sedation in one study 5
  • Avoid abrupt discontinuation as this may induce hypertensive crisis; clonidine must be tapered to avoid rebound hypertension 2
  • Doses used specifically for treating hot flashes generally do not significantly affect blood pressure 2

Special Considerations

  • For patients with renal impairment, start with a lower initial dose and monitor carefully 1
  • No supplemental dosing is needed following hemodialysis 1
  • Clonidine is generally reserved as a later-line therapy for hot flashes/night sweats due to CNS adverse effects, especially in older adults 2
  • For PTSD-related night sweats, prazosin (an alpha-1 blocker) is considered first-line with stronger evidence (Level A recommendation) compared to clonidine (Level C recommendation) 2

Alternative Options

  • If clonidine is ineffective or poorly tolerated, consider:
    • Prazosin (first-line for PTSD-related nightmares) 2
    • SSRI/SNRIs (particularly for menopausal hot flashes) 2
    • Gabapentin (particularly effective for hot flashes in breast cancer patients) 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Dose-dependent suppression of norepinephrine appearance rate in plasma by clonidine in man.

The Journal of clinical endocrinology and metabolism, 1984

Research

Clonidine decreases vasoconstriction and shivering thresholds, without affecting the sweating threshold.

Canadian journal of anaesthesia = Journal canadien d'anesthesie, 1997

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.